Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Generic Health

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia's Parliament, serves to regulate therapeutic goods, ensuring they meet safety, quality, and efficacy standards. This Act was introduced to address the need for a cohesive framework governing the importation, supply, and regulation of therapeutic goods, thereby protecting public health. The Therapeutic Goods Administration, as a delegate of the Secretary of the Department of Health, exercises its powers under the Act to facilitate the import and supply of therapeutic goods that may not fully comply with certain regulatory requirements, provided they meet broader public health objectives. In this instance, the TGA consented to the importation and supply of specific batches of ibuprofen and naproxen products under sections 14 and 14A of the Act, recognising their therapeutic benefits while ensuring that they adhere to the overarching goals of safeguarding public health. The policy objective in this instance was to allow the continued availability of these medications with minor label discrepancies until they could be fully compliant with forthcoming legislative changes.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including the importation, supply, and labelling of such products. Under sections 14 and 14A of this Act, the Secretary of the Department of Health can consent to the supply of goods that do not fully comply with the therapeutic goods standards. This was applied in the case of Generic Health Pty Ltd, which sought consent to import and supply certain batches of Pharmacy Action Ibuprofen, Ibuprofen Plus Codeine, and Naproxen Sodium tablets. These products did not conform to the label requirements specified in the Therapeutic Goods Order No. 69, as they did not include new warning statements mandated by a legislative instrument effective from 12 December 2015. The consent granted to Generic Health Pty Ltd allows for the continued supply of these specific batches until 12 June 2017, subject to conditions ensuring that the labels used are those previously approved by the Therapeutic Goods Administration. This consent is limited to the specified batches and timeframe, and does not affect the broader application of the Therapeutic Goods Act or its associated regulations.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes sections 14 and 14A, which provide the legal framework for granting consent for the importation and supply of therapeutic goods that do not fully comply with certain regulatory standards. In this instance, sections 14 and 14A were invoked to allow the importation and supply of specific batches of Pharmacy Action Ibuprofen 200mg capsules, Pharmacy Action Ibuprofen Plus Codeine tablets, and Pharmacy Action Period Pain Relief naproxen sodium tablets. These products did not meet the requirements of paragraph 3(2)(g) of Therapeutic Goods Order No. 69, which pertains to the general requirements for labels for medicines. Specifically, the product labels did not include all of the new warning statements that would be mandatory under a legislative instrument made by the Minister under subsection 3(5A) of the Act, effective from 12 December 2015. This consent, granted on 11 December 2015, applied only to the nominated batches and was effective until 12 June 2017. The consent granted under sections 14 and 14A of the Act imposed several obligations on Generic Health Pty Ltd and the Therapeutic Goods Administration (TGA). Firstly, the consent was limited to the specific batches of products mentioned in the notice. Secondly, the consent required that the product labels used were those previously approved by the TGA for these products, ensuring that the labels were consistent with existing regulatory standards. Additionally, the consent was subject to certain conditions, although these conditions were not detailed in the notice. This consent mechanism allowed the products to be imported and supplied while the necessary label updates were being made. Breach of the conditions of the consent or failure to comply with the terms of the consent could result in various legal consequences. Under the Act, non-compliance with the terms of consent granted under sections 14 and 14A could lead to civil and criminal penalties. Civil penalties may include fines, while criminal penalties could result in imprisonment, depending on the severity and intent of the breach. However, the specific penalties for breaches in this context are not detailed in the notice but would be determined by the relevant courts based on the circumstances of the breach. It is important for Generic Health Pty Ltd and other entities governed by the Act to adhere strictly to the terms and conditions of any consent granted to avoid these potential legal repercussions.